Nucl Med Mol Imaging.
2023 Dec;57(6):257-264. 10.1007/s13139-023-00811-8.
Comparison of Prognostic Value Between Stimulated and Nonstimulated Thyroglobulins in Differentiated Thyroid Cancer: A Retrospective Study
- Affiliations
-
- 1Department of Nuclear Medicine, Kyungpook National University Hospital, 130 Dongdeok‑Ro, Jung Gu, Daegu, Republic of Korea 41944
- 2Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
- 3Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
- KMID: 2549936
- DOI: http://doi.org/10.1007/s13139-023-00811-8
Abstract
- Purpose
The growing incidence of differentiated thyroid cancer (DTC) demands dependable prognostic factors to guide follow-up and treatment plans. This study investigated the prognostic value of response to therapy (RTT) assessment using TSH stimulated-thyroglobulin (sti-Tg) and nonstimulated-thyroglobulin (nonsti-Tg) and evaluates whether RTT using nonsti-Tg (nonstiRTT) can replace RTT using sti-Tg (stiRTT) in clinical practice to improve patients’ quality of life during assessment.
Methods
We enrolled 419 DTC patients who underwent total thyroidectomy, radioactive iodine (RAI) therapy, and Tg assessment. Patients with structural incomplete responses were excluded. Initial RTT assessments based on the 2015 American Thyroid Association guidelines (excellent response; ER, indeterminate response, biochemical incomplete response) were performed 6–24 months after RAI therapy. The second RTT assessments were performed 6–24 months after the first assessment. Statistical analysis for recurrence-free survival (RFS) was done with the log-rank test for stiRTT and nonstiRTT.
Results
Although initial stiRTT and nonstiRTT were significant predictors for RFS (p < 0.0001), stiRTT provided better RFS prediction than nonstiRTT. The RFS analysis of the second RTT assessment demonstrated statistical significance only for stiRTT (p < 0.0001). In 116 patients classified as ER on initial stiRTT, there was no RFS difference between patients classified as ER on either second stiRTT or nonstiRTT.
Conclusion
The prognostic power of stiRTT surpasses that of nonstiRTT in both the initial and second RTT assessment. Nevertheless, among patients classified as ER on initial stiRTT, a second stiRTT may not be required for those classified as ER on the second nonstiRTT.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Preoperative Staging of Well Differentiated Thyroid Cancer: US Is Enough?
- Molecular Pathogenesis and Targeted Therapies in Well-Differentiated Thyroid Carcinoma
- Postoperative Follow-Up of Differentiated Thyroid Cancer: Use of Thyroglobulin Assay
- ATA Guideline in a View Point of Nuclear Medicine
- Second Primary Malignancy after Radioiodine Treatment of Thyroid Disease: Current Status
